menu

Practical Management of Variceal Bleeding and Hepatorenal Syndrome

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Practical Management of Variceal Bleeding and Hepatorenal Syndrome

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.

  • Disclosure of Conflicts of Interest

    To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. All relevant conflicts of interest will have been mitigated and advised to the participants prior to the start of the activity.

    Michael P. Curry, MD
    Albireo (Consultant); Alexion (Consultant); CareDx (Grants/Research Support); Intercept Pharmaceuticals (Grants/Research Support); Mallinckrodt Pharmaceuticals (Consultant); Pfizer (Adverse Event Committee); Sonic Incytes (Grants/Research Support, Consultant); Viking Therapeutics (Stocks); UpToDate (Royalties)

    Andrew P. Keaveny, MD
    Biovie, Inc. (Grants/Research Support, Consultant); Hepquant (Grants/Research Support); UpToDate (Royalties)

    Don C. Rockey, MD
    AstraZeneca (Grants/Research Support); Galectin Therapeutics (Grants/Research Support); Gilead (Grants/Research Support); Novo Nordisk (Grants/Research Support); Ocelot Pharmaceuticals (Grants/Research Support); Salix Pharmaceuticals (Grants/Research Support) 

    All additional planning committee members, staff and reviewers of CiME and Purdue University College of Pharmacy have no relationships to disclose.

     

  • Target Audience

    This continuing medical education activity is intended to meet the needs of gastroenterologists, hepatologists, nephrologists, critical care teams and other health care professionals managing patients with liver disease and extrahepatic complications of cirrhosis

  • Learning Objectives

    After completing this activity, participants will be better able to:

           1. Describe appropriate assessment procedures, pharmacologic and interventional strategies for extrahepatic complications of cirrhosis

           2.  Apply proactive evidence-based pharmacotherapy to patients with decompensated cirrhosis who meet criteria for HRS/AKI

  • Accreditation and Credit Designation Statements

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and CiME.

    Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacists
    Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-23-043-H01-P, 0.5 contact hour (0.05 CEU).

    Purdue reports pharmacy credits to CPE Monitor, which will authenticate and pass this data to the National Association of Boards of Pharmacy (NABP). Upon completion of this reporting, pharmacists and pharmacy technicians will be able to access their NABP profile and capture a transcript of these earned credits.

  • Disclaimer

    This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

     The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of the commercial supporter, any other manufacturer of pharmaceuticals or devices, Purdue University College of Pharmacy, or CiME. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

    Copyright © 2023 Purdue University College of Pharmacy and CiME, LLC. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

    recording, or any information storage and retrieval systems, without permission in writing.

     

     

  • Provider(s)/Educational Partner(s)

    Jointly provided by

  • Commercial Support

    Supported by an educational grant from Mallinckrodt Pharmaceuticals.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.

  • Disclosure of Conflicts of Interest

    To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. All relevant conflicts of interest will have been mitigated and advised to the participants prior to the start of the activity.

    Michael P. Curry, MD
    Albireo (Consultant); Alexion (Consultant); CareDx (Grants/Research Support); Intercept Pharmaceuticals (Grants/Research Support); Mallinckrodt Pharmaceuticals (Consultant); Pfizer (Adverse Event Committee); Sonic Incytes (Grants/Research Support, Consultant); Viking Therapeutics (Stocks); UpToDate (Royalties)

    Andrew P. Keaveny, MD
    Biovie, Inc. (Grants/Research Support, Consultant); Hepquant (Grants/Research Support); UpToDate (Royalties)

    Don C. Rockey, MD
    AstraZeneca (Grants/Research Support); Galectin Therapeutics (Grants/Research Support); Gilead (Grants/Research Support); Novo Nordisk (Grants/Research Support); Ocelot Pharmaceuticals (Grants/Research Support); Salix Pharmaceuticals (Grants/Research Support) 

    All additional planning committee members, staff and reviewers of CiME and Purdue University College of Pharmacy have no relationships to disclose.

     

  • Target Audience

    This continuing medical education activity is intended to meet the needs of gastroenterologists, hepatologists, nephrologists, critical care teams and other health care professionals managing patients with liver disease and extrahepatic complications of cirrhosis

  • Learning Objectives

    After completing this activity, participants will be better able to:

           1. Describe appropriate assessment procedures, pharmacologic and interventional strategies for extrahepatic complications of cirrhosis

           2.  Apply proactive evidence-based pharmacotherapy to patients with decompensated cirrhosis who meet criteria for HRS/AKI

  • Accreditation and Credit Designation Statements

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and CiME.

    Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacists
    Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-23-043-H01-P, 0.5 contact hour (0.05 CEU).

    Purdue reports pharmacy credits to CPE Monitor, which will authenticate and pass this data to the National Association of Boards of Pharmacy (NABP). Upon completion of this reporting, pharmacists and pharmacy technicians will be able to access their NABP profile and capture a transcript of these earned credits.

  • Disclaimer

    This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

     The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of the commercial supporter, any other manufacturer of pharmaceuticals or devices, Purdue University College of Pharmacy, or CiME. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

    Copyright © 2023 Purdue University College of Pharmacy and CiME, LLC. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

    recording, or any information storage and retrieval systems, without permission in writing.

     

     

  • Provider(s)/Educational Partner(s)

    Jointly provided by

  • Commercial Support

    Supported by an educational grant from Mallinckrodt Pharmaceuticals.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 Apr 2024